Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunotherapy
Data on immunotherapy published by researchers at Duke University, Division of Neurosurgery
January 28th, 2009
Data detailed in 'Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma' have been presented. According to recent research published in the journal Seminars In Immunology, "Conventional therapies for malignant gliomas (MGs) fail to target tumor cells exclusively, such that their efficacy is ultimately limited by non-specific toxicity. Immunologic targeting of tumor-specific gene mutations, however, may allow more precise eradication of neoplastic cells." "The epidermal growth factor receptor variant III (EGFRvIII) is a consistent tumor-specific mutation that is widely expressed in MGs and other neoplasms. This mutation...
Source: Vaccine Weekly (2009-01-28)
|
